Itus Corp Cmn (ITUS) 3.26 $ITUS ITUS Corporation

New Post Public Reply Private Reply Replies (0) Message Board

Jun 22, 2016 at 9:09 PM

Itus Corp Cmn (ITUS) 3.26 $ITUS

ITUS Corporation (Nasdaq: ITUS) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Jun 02, 9:00AM CDT
What:
ITUS: 3.26 (-0.07), NDAQ: 63.09 (+0.12)

ITUS to Ring June 3, 2016 Nasdaq Closing Bell and Launch New Cancer Social Media Campaign
Marketwired - Tue May 31, 8:02AM CDT
LOS ANGELES, CA--(Marketwired - May 31, 2016) - ITUS Corporation (NASDAQ: ITUS) today announced that to commemorate National Cancer Survivor's Day on June 5, company representatives will ring the June 3, 2016 closing bell of The Nasdaq Stock Market. The occasion will also mark the official launch of a new cancer social media campaign entitled "Let's Get Crack'n Against Cancer."
ITUS: 3.26 (-0.07)

ITUS Featured on New York Radio Program
Marketwired - Thu Apr 28, 8:02AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS) today announced that its President and CEO, Robert Berman, recently appeared on "Westchester On the Level with Narog and Aris," a news show broadcast by WHYT Radio. During the segment, Mr. Berman is interviewed by the show's host and Yonkers Tribune Editor, Hezi Aris.
ITUS: 3.26 (-0.07)

ITUS Featured on FOX News Health Segment
Marketwired - Mon Apr 25, 8:02AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its President and CEO, Robert Berman, recently appeared on a health segment on cancer for FOX News. During the segment, Mr. Berman is interviewed by Fox News Channel's Senior Managing Editor for Health News, Dr. Manny Alveraz.
ITUS: 3.26 (-0.07)

ITUS Subsidiary Anixa Diagnostics Corporation Demonstrates Efficacy of Early Cancer Detection Platform With Lung Cancer
Marketwire Canada - Tue Apr 19, 8:00AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS) today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has successfully demonstrated that its Ccheka"c early cancer detection platform can be used to identify the presence of lung cancer. The company will now expand its ongoing biomarker study to include additional lung cancer samples. Anixa previously announced results from the study with breast cancer patients.
ITUS: 3.26 (-0.07)

ITUS Featured on Several National and Local Radio Broadcasts
Marketwired - Thu Apr 14, 8:02AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS) today announced that its President and CEO, Robert Berman, has recently appeared on several national and local radio broadcasts. Most recently, Mr. Berman appeared on NPR affiliate WFUV in New York. Last week, Mr. Berman was an hour-long guest on Joni Aldrich SOS, the iHeartRadio show hosted by nationally acclaimed cancer advocate Joni Aldrich.
ITUS: 3.26 (-0.07)

American Cancer Society Vice Chairman of the National Board of Directors, Dr. Arnold Baskies, Joins Scientific Advisory Board for ITUS Subsidiary Anixa Diagnostics Corporation
Marketwired - Mon Jan 25, 8:01AM CST
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Arnold Baskies, the Vice Chairman of the Board of Directors of the American Cancer Society, to its Scientific Advisory Board. Dr. Baskies previously served as Chief Science Officer to the Board of Directors of the American Cancer Society and as President of the American Cancer Society of New York and New Jersey. He has been appointed by every New Jersey governor through 2015 to serve as Chair of the New Jersey Governor's Task Force on Cancer Prevention, Early Detection & Treatment.
ITUS: 3.26 (-0.07)

ITUS Subsidiary Anixa Diagnostics Corporation Appoints Dr. Michael Shepard to Its Scientific Advisory Board
Marketwired - Mon Dec 07, 8:01AM CST
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Michael Shepard to its Scientific Advisory Board. Dr. Shepard is a pioneer in modern cancer research, whose many successes include work that lead to the discovery, development and launch of Herceptin, one of the best-selling cancer drugs of all time, used to treat breast cancer. Cumulative Herceptin sales have totaled more than $50 Billion, including sales in 2014 of greater than $7 Billion. Herceptin's approval opened the door for many other antibody therapies for cancer. For his work in this field, Dr. Shepard received the very prestigious Warren Alpert Prize, an annual award granted by The Warren Alpert Foundation, in association with Harvard Medical School, to scientists, physicians, and researchers, whose research constitutes a seminal scientific finding that holds great promise of ultimately changing our understanding of or ability to treat disease.
ITUS: 3.26 (-0.07)

ITUS Subsidiary Anixa Diagnostics Corporation Announces Initial Cancer Biomarker Results
Marketwired - Mon Oct 05, 8:02AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, in collaboration with The Wistar Institute, a National Cancer Institute-designated Cancer Center, has achieved very favorable initial results in a cancer biomarker study, successfully demonstrating the efficacy of Anixa's cancer screening technology. Wistar evaluated blood samples from a small group of patients with differing severities of breast cancer to determine the presence or absence of unique and anomalous biomarkers. Wistar also studied blood samples from a small group of healthy patients. The initial results showed the presence of the biomarkers in 100% of the cancer patients tested. Equally as important, none of the healthy patient blood samples contained the biomarkers.
ITUS: 3.26 (-0.07)

ITUS Subsidiary Auction Acceleration Corporation Enters Into Settlement and License Agreement With eBay, Vendio, & Auctiva
Marketwired - Wed Jul 15, 6:00AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Auction Acceleration Corporation ("AAC"

, has entered into a Settlement and License Agreement with eBay, Inc., Auctiva, LLC, and Vendio Services, LLC.
ITUS: 3.26 (-0.07), EBAY: 24.34 (-0.36)

ITUS Subsidiary Anixa Diagnostics Enters Into Collaborative Research Agreement With The Wistar Institute, a Leading Cancer Research Institute
Marketwired - Tue Jul 14, 11:52AM CDT
ITUS Corporation ("ITUS"

(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has entered into a Collaborative Research Agreement with The Wistar Institute, located on the campus of the University of Pennsylvania in Philadelphia, Pennsylvania, to further the development of a cancer screening test. Founded in 1892 as the nation's first independent biomedical research institute, Wistar is an international leader in the biomedical research fields of cancer, immunology and infectious diseases, a National Cancer Institute (NCI)-designated Cancer Center, and part of the NCI's select network of national cancer research centers, holding an 'Exceptional' rating -- the highest possible ranking awarded.
ITUS: 3.26 (-0.07)

ITUS Announces Uplisting to NASDAQ
Marketwired - Thu Jul 09, 3:01PM CDT
ITUS Corporation ("ITUS"

(OTCQB: ITUS) today announced that The NASDAQ Stock Market LLC has approved the listing of the Company's stock for trading on The NASDAQ Capital Market. Trading of the Company's securities on The NASDAQ Capital Market will commence effective with the opening of business on Friday, July 10, 2015.
ITUS: 3.26 (-0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FOTON Accelerates Global Push with European Focus

The Road to Global Dominance Ever feel like someone’s racing past you while others try to catch up? That’s FOTON in the relentless world of commercial vehicles. This juggernaut of a company isn't just satisfied with leading the pack; they’ve got their eyes set on redefines the game, especially with their new moves in Europe. A Shift in Strategy Right now, the...

KuCoin's KCUSD Tackles Stablecoin Idle Capital Problem

KuCoin's Bold Move with KCUSD Folks, the cat's outta the bag with KuCoin's latest maneuver—introducing KCUSD. At first glance, it seems like they're just introducing another fancy stablecoin product, but peel the onion and there's more to it. We're talking about shaking up how stablecoins sit tight doing nada in the crypto world. KCUSD is out to make those idle balances...

TECNO CAMON Slim 5G: Where Art Meets Tech

Unveiling the TECNO CAMON Slim 5G Okay, so imagine a tech brand saying, 'Why not make a phone that’s as much an art piece as it is a gadget?' TECNO just pulled this off with their latest CAMON Slim 5G. The thing's a sleek marvel measuring in at just 6.39mm. Seems like they took a fat-free diet approach to phone design, and not on the digital calories either. A Slim Body...

Huion Kamvas Pad 12: A Creative Power Tool

The Kamvas Pad 12 Hits the Market In a crowded tablet market that's fierce with innovation, Huion tossed their latest tool into the ring—the Kamvas Pad 12. Now, anyone who’s been watching the digital art scene won't be surprised that Huion, with its decade and a half of digital prowess, is pulling another tablet trick out of its hat. Key Features and Innovations If...

Summit Tackles BRI Infrastructure's Role in Global SDGs

A Bold Gathering with Lofty Goals Ever watch a room of world leaders debate the finer nuances of sustainable infrastructure? That's something Singapore pulled off on September 6, 2026, with the Second Global Business Summit on Belt and Road Infrastructure Investment. These aren't just any ordinary suits sitting around in a conference room. We're talking about a dynamic...

Clover's RSV Combo Vaccine Shows Promise in Trials

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Europe's Largest Carbon Capture Facility Launches

A New Chapter in Industrial Decarbonization Today's not just your average ribbon-cutting ceremony; it's a landmark turn in our journey toward a cleaner Europe. Yara's Sluiskil plant in the Netherlands just fired up Europe's biggest carbon capture facility, marking a crucial pivot point in industrial decarbonization. We're talking about capturing a staggering 800,000 tons...

Aroa Biosurgery Reports Low Infection Rates: A Milestone

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

AION UT Sets New Safety Standard in Euro NCAP 2026

The New Gold Standard in Safety for Small EVs Hop into your favorite auto forum and you'll hear more than a buzz—it's a full-blown ruckus. The reason? GAC’s AION UT just nabbed a 2026 Euro NCAP Five-Star Safety Rating. Now, this isn’t just another accolade in a crowded trophy room; it’s a statement, a seismic shift in how small electric vehicles stack up in terms...

Ping An Climbs Sustainability Ladder, Scores A+ Rating

Sustainability Triumph for Ping An: A+ Upgrade Ping An Insurance (Group) Company of China, Ltd. is having quite the moment, snagging an A+ in the latest 2026 Sustainability Rating from Hang Seng Indexes Company. This ain't just a one-time pat on the back—it's the third year of consecutive improvement. Looks like Ping An's focus on ESG efforts is finally getting the...